Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’ (with Colin Lindsay)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Expert comment: AMG 510 KRAS inhibitor trial results – ‘A good start’ (with Colin Lindsay)
-
Narrated by:
-
By:
About this listen
Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation – in patients with locally advanced or metastatic non-small-cell lung cancer.
Find more on Medicine Matters oncology
More from WCLC 2019
adbl_web_global_use_to_activate_webcro805_stickypopup
No reviews yet